MHC-BOUND, SIV-DERIVED, CTL AND HTL EPITOPES

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。为了开发HIV疫苗，我们将确定细胞毒性和辅助性T细胞的额外表位，并利用这些信息开发用于后续免疫反应的独特试剂。确定了Mamu-B*01的结合基序，筛选了潜在的SIV肽，并筛选了35个新的Mamu-B*01表位。尽管其频率很高，但我们无法找到SIV的任何B*01表位，并且发现先前发表的一个表位是错误的。我们继续开发额外的四聚体，现在有21个Mamu-A*01, 15个Mamu-A*02, 6个Mamu-B*17四聚体在常规生产中，以及更多的正在开发中。本研究使用WNPRC免疫遗传与病毒学服务和动物服务。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To work on developing a vaccine for HIV, we will identify additional epitopes for cytotoxic and helper T cells and use this information to develop unique reagents for following immune responses. The binding motif for Mamu-B*01 was defined, potential SIV peptides screened and 35 new Mamu-B*01 epitopes are being screened. Despite its high frequency, we have been unable to find any B*01 epitopes for SIV and have found that one epitope previously published is erroneous. We have continued to develop additional tetramers and now have 21 Mamu-A*01, 15 Mamu-A*02, 6 Mamu-B*17 tetramers in regular production, as well as many more under development. This research used WNPRC Immunogenetics & Virology Services and Animal Services.